Table 2.
Cardiovascular Outcomes in Patients Enrolled in Asia and Outside Asia
| Patients Enrolled in Asia (n = 1,096) | Patients Not Enrolled in Asia (n = 3,648) | |
|---|---|---|
| Primary composite endpointa | ||
| Event rate per 100 person-y | 13.9 (12.0-16.0) | 13.4 (12.5-14.5) |
| Unadjusted HR (95% CI) | 1.00 (0.85-1.18), P = 0.98 | 1.00 (referent) |
| Adjusted HR (95% CI) | 1.19 (0.99-1.42), P = 0.06 | 1.00 (referent) |
| Cardiovascular death | ||
| Event rate per 100 person-y | 6.7 (5.5-8.2) | 7.3 (6.6-8.1) |
| Unadjusted HR (95% CI) | 0.93 (0.74-1.16), P = 0.50 | 1.00 (referent) |
| Adjusted HR (95% CI) | 0.98 (0.77-1.26), P = 0.90 | 1.00 (referent) |
| Worsening HF event | ||
| Event rate per 100 person-y | 8.6 (7.2-10.3) | 8.6 (7.8-9.4) |
| Unadjusted HR (95% CI) | 0.95 (0.77-1.16), P = 0.60 | 1.00 (referent) |
| Adjusted HR (95% CI) | 1.22 (0.98-1.53), P = 0.08 | 1.00 (referent) |
| All-cause mortality | ||
| Event rate per 100 person-y | 7.6 (6.3-9.2) | 9.0 (8.2-9.8) |
| Unadjusted HR (95% CI) | 0.86 (0.70-1.05), P = 0.15 | 1.00 (referent) |
| Adjusted HR (95% CI) | 0.93 (0.74-1.17), P = 0.56 | 1.00 (referent) |
| Total heart failure hospitalizations and cardiovascular deathb | ||
| Event rate per 100 person-y | 18.5 (16.4-20.8) | 19.0 (17.9-20.2) |
| Unadjusted RR (95% CI) | 0.96 (0.80-1.15), P = 0.62 | 1.00 (referent) |
| Adjusted RR (95% CI) | 1.13 (0.93-1.37), P = 0.23 | 1.00 (referent) |
Unadjusted analysis includes factors for Asia/not Asia, randomized treatment, and history of HF hospitalization and is stratified by diabetes status. Adjusted analysis includes factors for Asia/not Asia, randomized treatment, history of heart failure hospitalization, age, sex, heart rate, systolic blood pressure, BMI, ischemic etiology of heart failure, LVEF, NYHA functional class, NT-proBNP, atrial fibrillation, and eGFR (and stratified by type 2 diabetes status).
Abbreviations as in Table 1.
The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or death from cardiovascular causes.
Risk estimate presented is a rate ratio (RR).